Xencor Inc. ((XNCR)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
In a recent update, Xencor Inc. has completed a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors.’ The study aimed to assess the safety and tolerability of XmAb541, a monoclonal bispecific antibody, and to determine optimal dosing for future research. This investigational drug is intended to improve outcomes in patients with advanced solid tumors.
The intervention tested was XmAb541, administered either intravenously or subcutaneously. It is designed to target and treat advanced solid tumors by leveraging its bispecific antibody properties.
The study followed an interventional design with a sequential intervention model, focusing on treatment. There was no masking involved, meaning all participants and researchers were aware of the treatment being administered. The primary goal was to establish a safe dosage for XmAb541.
Key dates for this study include its start on April 4, 2024, and its last update on August 4, 2025. These dates are crucial as they mark the timeline of the study’s progression and the availability of updated information for stakeholders.
The completion of this study could potentially influence Xencor Inc.’s stock performance positively, as successful results may boost investor confidence. This development is particularly relevant in the competitive landscape of oncology treatments, where advancements can significantly impact market dynamics.
The study is now completed, and further details are available on the ClinicalTrials portal.